Calcimedica, INC Form 4 insider transactions

CalciMedica, Inc.'s Chief Executive Officer, Rachel Leheny, reported a planned acquisition of 2,500 shares of common stock at $2.47 per share, effective July 14, 2025, under a Rule 10b5-1 plan.

Eric W. Roberts, CalciMedica's Chief Business Officer and a 10% owner, acquired 5,000 shares of common stock through a pre-arranged trading plan.

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reported an indirect acquisition of 1,000 shares of common stock by his spouse at a price of $1.85 per share.

Eric W. Roberts, Chief Business Officer, Director, and 10% Owner of CalciMedica, Inc., purchased 4,500 shares of common stock for approximately $6,482.70, increasing his total beneficial ownership to 997,410 shares.

CalciMedica, Inc.'s Chief Medical Officer, Sudarshan Hebbar, was granted 83,300 employee stock options with an exercise price of $1.53 per share, following stockholder approval of an amended equity incentive plan.

CalciMedica, Inc.'s Chief Financial Officer, Stephen Bardin, has reported an acquisition of 2,000 shares of common stock and a grant of 20,000 employee stock options, signaling increased insider ownership.

CalciMedica, Inc. has reported that its Chief Scientific Officer, Kenneth A. Stauderman, was granted 47,125 employee stock options with an exercise price of $1.53, following stockholder approval of an amended equity incentive plan.

CalciMedica, Inc. Chief Business Officer Eric W. Roberts was granted 72,750 employee stock options with an exercise price of $1.53, following shareholder approval of the company's amended equity incentive plan.

CalciMedica, Inc.'s President and COO, Michael J. Dunn, was granted 47,125 employee stock options following stockholder approval of an amended equity incentive plan.

CalciMedica, Inc. CEO A. Rachel Leheny was granted 77,625 employee stock options with an exercise price of $1.53 per share, following shareholder approval of an amendment to the company's 2023 Equity Incentive Plan.

CalciMedica, Inc. (CALC) has reported that Director Frederic Guerard was granted 40,000 stock options following stockholder approval of an amended equity incentive plan.

CalciMedica, Inc. Director Alan Glicklich was granted a total of 39,166 stock options with exercise prices of $1.53 and $1.65, following stockholder approval of the company's amended equity incentive plan.

CalciMedica, Inc. Director Allan Shaw was granted a total of 54,844 stock options with exercise prices of $1.53 and $1.65, following the company's stockholder approval of an amended equity incentive plan.

CalciMedica, Inc. Director Robert N. Wilson was granted a total of 68,593 stock options with exercise prices of $1.53 and $1.65, following stockholder approval of the Amended 2023 Equity Incentive Plan.

CalciMedica, Inc. (CALC) reported that Director and 10% Owner Fred A. Middleton was granted a total of 46,249 stock options on June 24, 2025, following shareholder approval of the Amended 2023 Equity Incentive Plan.

Eric W. Roberts, CalciMedica's Chief Business Officer, Director, and 10% Owner, acquired 5,000 shares of common stock, signaling increased insider confidence.

Eric W. Roberts, CalciMedica's Chief Business Officer, Director, and 10% Owner, reported recent purchases of common stock totaling 10,100 shares, signaling increased insider confidence.

CalciMedica, Inc.'s Chief Financial Officer, Stephen Bardin, acquired 1,000 shares of common stock at $1.69 per share, increasing his direct beneficial ownership to 41,000 shares.

CalciMedica's Chief Financial Officer, Stephen Bardin, reports the acquisition of stock options.

Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc., reports the acquisition of employee stock options.

Michael J. Dunn, President and COO of CalciMedica, reports the acquisition of employee stock options.

Eric W. Roberts, Chief Business Officer of CalciMedica, Inc., reports the acquisition of stock options.

CalciMedica's Chief Medical Officer, Sudarshan Hebbar, reports the acquisition of stock options.

Rachel A. Leheny, CEO of CalciMedica, Inc., reports the acquisition of 285,000 employee stock options.

Director Alan Glicklich of CalciMedica, Inc. was granted stock options for 20,000 shares on January 15, 2025.

Fred A. Middleton, a director at CalciMedica, acquired 4,800 shares of common stock at $2.65 per share on December 6, 2024.

Eric W. Roberts, Chief Business Officer of CalciMedica, amends a previous SEC Form 4 filing to include the purchase of 3,000 shares of common stock held in his Roth IRA.

Sanderling Venture Partners and related entities report acquiring additional shares of CalciMedica, Inc. common stock at $3.75 per share.

Director Fred A. Middleton reports purchasing shares of CalciMedica, Inc. both directly and indirectly through associated investment funds.

CalciMedica's CEO, Rachel Leheny, recently purchased 20,000 shares of the company's common stock at a price of $3.75 per share.